84 243

Cited 90 times in

Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial

Authors
 C E Geyer  ;  W M Sikov  ;  J Huober  ;  H S Rugo  ;  N Wolmark  ;  J O'Shaughnessy  ;  D Maag  ;  M Untch  ;  M Golshan  ;  J Ponce Lorenzo  ;  O Metzger  ;  M Dunbar  ;  W F Symmans  ;  P Rastogi  ;  J H Sohn  ;  R Young  ;  G S Wright  ;  C Harkness  ;  K McIntyre  ;  D Yardley  ;  S Loibl 
Citation
 ANNALS OF ONCOLOGY, Vol.33(4) : 384-394, 2022-04 
Journal Title
ANNALS OF ONCOLOGY
ISSN
 0923-7534 
Issue Date
2022-04
MeSH
Antineoplastic Combined Chemotherapy Protocols / adverse effects ; Benzimidazoles ; Carboplatin ; Cyclophosphamide ; Doxorubicin ; Female ; Follow-Up Studies ; Humans ; Neoadjuvant Therapy* ; Paclitaxel ; Triple Negative Breast Neoplasms* / pathology
Keywords
carboplatin ; neoadjuvant chemotherapy ; phase III ; triple-negative breast cancer ; veliparib
Abstract
Background: Primary analyses of the phase III BrighTNess trial showed addition of carboplatin with/without veliparib to neoadjuvant chemotherapy significantly improved pathological complete response (pCR) rates with manageable acute toxicity in patients with triple-negative breast cancer (TNBC). Here, we report 4.5-year follow-up data from the trial.

Patients and methods: Women with untreated stage II-III TNBC were randomized (2 : 1 : 1) to paclitaxel (weekly for 12 doses) plus: (i) carboplatin (every 3 weeks for four cycles) plus veliparib (twice daily); (ii) carboplatin plus veliparib placebo; or (iii) carboplatin placebo plus veliparib placebo. All patients then received doxorubicin and cyclophosphamide every 2-3 weeks for four cycles. The primary endpoint was pCR. Secondary endpoints included event-free survival (EFS), overall survival (OS), and safety. Since the co-primary endpoint of increased pCR with carboplatin plus veliparib with paclitaxel versus carboplatin with paclitaxel was not met, secondary analyses are descriptive.

Results: Of 634 patients, 316 were randomized to carboplatin plus veliparib with paclitaxel, 160 to carboplatin with paclitaxel, and 158 to paclitaxel. With median follow-up of 4.5 years, the hazard ratio for EFS for carboplatin plus veliparib with paclitaxel versus paclitaxel was 0.63 [95% confidence interval (CI) 0.43-0.92, P = 0.02], but 1.12 (95% CI 0.72-1.72, P = 0.62) for carboplatin plus veliparib with paclitaxel versus carboplatin with paclitaxel. In post hoc analysis, the hazard ratio for EFS was 0.57 (95% CI 0.36-0.91, P = 0.02) for carboplatin with paclitaxel versus paclitaxel. OS did not differ significantly between treatment arms, nor did rates of myelodysplastic syndromes, acute myeloid leukemia, or other secondary malignancies.

Conclusions: Improvement in pCR with the addition of carboplatin was associated with long-term EFS benefit with a manageable safety profile, and without increasing the risk of second malignancies, whereas adding veliparib did not impact EFS. These findings support the addition of carboplatin to weekly paclitaxel followed by doxorubicin and cyclophosphamide neoadjuvant chemotherapy for early-stage TNBC.
Files in This Item:
T9992022688.pdf Download
DOI
10.1016/j.annonc.2022.01.009
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Sohn, Joo Hyuk(손주혁) ORCID logo https://orcid.org/0000-0002-2303-2764
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/193459
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links